Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study
UK cancer patients have been more severely impacted by the unfolding of the COVID-19 pandemic despite societal risk mitigation factors and rapid deferral of anticancer therapy. The increased frailty of UK cancer patients highlights high-risk groups that should be prioritised for anti-SARS-CoV-2 vaccination. Continued evaluation of long-term outcomes is warranted. (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 6, 2021 Category: Cancer & Oncology Authors: David J. Pinato, Lorenza Scotti, Alessandra Gennari, Emeline Colomba-Blameble, Saoirse Dolly, Angela Loizidou, John Chester, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Myria Galazi, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Rica Tags: Original Research Source Type: research

Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease
Nearly 4% of all patients with non-small-cell lung cancer (NSCLC) harbour epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) exon 20 mutations, lacking efficient response to pan-HER tyrosine kinase inhibitors (TKIs) (afatinib, lapatinib, neratinib or dacomitinib). Exon 20 of EGFR and HER2 contains two major regions, the α-C helix (residues 762–766 in EGFR and 770–774 in HER2) and the loop after the α-C helix (residues 767–774 in EGFR and 775–783 in HER2). (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 3, 2021 Category: Cancer & Oncology Authors: Rafael Rosell, Andres F. Cardona Zorrilla Tags: Editorial Source Type: research

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
The treatment of metastatic non –small-cell lung cancer (mNSCLC) patients with EGFR/HER2 exon 20 insertion mutation (i-mut) remains an unmet clinical need. Poziotinib, a new generation tyrosine kinase inhibitor, is currently under investigation as a potential targeted therapy. This compassionate study of its use aims to describe the activity/toxicity of poziotinib in mNSCLC with EGFR/HER2-exon-20-i-mut. (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 2, 2021 Category: Cancer & Oncology Authors: Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Federico Nichetti, Sara Manglaviti, Mario Occhipinti, Alice L Tags: Original Research Source Type: research

SARS-CoV-2 vaccination for patients with solid cancer: review and point of view of a French oncology inter-group (CGO, TNCD, UNICANCER)
The impacts of SARS-CoV-2 pandemic on cancer care are multiple, entailing a high risk of death from COVID-19 in cancer patients treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in cancer patients and also to restore normal cancer care.Cancer patients to be targeted for vaccination are difficult to define due to the limited contribution of these patients in the phase III trials testing the different vaccines. It seems appropriate to vaccinate not only cancer patients with ongoing treatment or with a treatment having been completed less than 3 years ago, but ...
Source: European Journal of Cancer - April 1, 2021 Category: Cancer & Oncology Authors: David Tougeron, Maxime Hentzien, Barbara Seitz-Polski, Firouze Bani-Sadr, Jean Bourhis, Michel Ducreux, S ébastien Gaujoux, Philippe Gorphe, Boris Guiu, Khe Hoang-Xuan, Florence Huguet, Thierry Lecomte, Astrid Lièvre, Christophe Louvet, Léon Maggiori, Tags: Current Perspective Source Type: research

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients
Cancer patients are considered as highly vulnerable to COVID-19 pandemic. However, delaying cancer specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients ’ immune system responds to SARS-CoV-2 virus. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 26, 2021 Category: Cancer & Oncology Authors: Laura Mansi, Laurie Spehner, Etienne Daguindau, Kevin Bouiller, Hamadi Almotlak, Ulrich Stein, Adeline Bouard, Stefano Kim, Elodie Klajer, Marine Jary, Guillaume Meynard, Ang élique Vienot, Charlée Nardin, Fernando Bazan, Quentin Lepiller, Virginie West Tags: Current Perspective Source Type: research

High levels of TNF α in patients with COVID-19 refractory to tocilizumab
Recently, Feldmann et al. in Lancet suggested investigating TNF alpha blocker therapies for patients with COVID-19 at high risk of developing a life-threatening form1. The cytokine release syndrome and immuno-thrombosis induced by Sars-CoV2 mostly explains the severity of coronavirus disease 2019 (COVID-19)2,3. In a recent issue of Nature Medicine, Del Valle et al. reported the plasma levels of IL-6, IL-8, tumor necrosis factor (TNF)- α and IL-1β in patients hospitalized for COVID-197. They highlighted in a comprehensive multivariate analysis that high plasma levels of IL-6 and TNF-α remained significantly...
Source: European Journal of Cancer - March 20, 2021 Category: Cancer & Oncology Authors: F.X. Danlos, F. Ackermann, J. Rohmer, M. Roumier, A. Marabelle, J.M. Michot Tags: Letter to the Editor Source Type: research

Abscopal anti-tumor effect in a patient with melanoma and COVID-19
We report here the first case of abscopal effect in a patient treated with radiotherapy for a metastatic melanoma during the course of an infection by the new coronavirus SARS-CoV-2, in a melanoma patient. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 14, 2021 Category: Cancer & Oncology Authors: Hugo Herrscher, Benoit Sauer, Pierre Truntzer, Caroline Robert Tags: Letter to the Editor Source Type: research

Erratum to ‘Identification of nephronectin as a new target for IGF1 action’ [Eur J Canc 141 (2020) Pages 115–127]
The publisher regrets that Figure  2 was incomplete in the published article. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 13, 2021 Category: Cancer & Oncology Authors: Rive Sarfstein, Lena Lapkina-Gendler, Karthik Nagaraj, Zvi Laron, Haim Werner Tags: Erratum Source Type: research

Hematological immune related adverse events after treatment with immune checkpoint inhibitors
With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 8, 2021 Category: Cancer & Oncology Authors: Rafaela Kramer, Anne Zaremba, Alvaro Moreira, Selma Ugurel, Douglas B. Johnson, Jessica C. Hassel, Martin Salzmann, Anja Gesierich, Alison Weppler, Lavinia Spain, Carmen Loquai, Milena Dudda, Claudia Pf öhler, Adriana Hepner, Georgina V. Long, Alexander Tags: Original Research Source Type: research

Corrigendum to “Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO studyˮ [Eur J Canc 144 (2021) 341–350]
The authors regret that the numbers of bone metastasis in this LEO trial (Table 1) need to be corrected as follows: (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 7, 2021 Category: Cancer & Oncology Authors: Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim Tags: Corrigendum Source Type: research

A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy
Treatments for metastatic melanoma have evolved considerably in recent years with the development of targeted therapy and checkpoint inhibitors. These treatments improve both progression-free survival and overall survival. For patients with a BRAF V600 mutation, the use of dual targeted therapy combining an anti-BRAF and an anti-MEK allowing a rapid response of the disease has been established [1]. However, approximately 50% of melanomas do not have a BRAF V600 mutation [2]. For such patients, treatment options are more limited with the use of checkpoint inhibitors and chemotherapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 5, 2021 Category: Cancer & Oncology Authors: Aliz é Pacaud, Samuel Amintas, Lise Boussemart, David Cappellen, Emilie Gérard Tags: Letter to the Editor Source Type: research

Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas
A group of patients with adult-type soft tissue sarcoma is at high risk of local recurrence and distant metastases. Age, tumour site, histological subtype, tumour size and grade have been identified as the most important independent adverse prognostic factors. Macroscopically complete tumour resection is considered as the mainstay of treatment with the addition of preoperative or postoperative radiotherapy for extremity or trunk localisation. Retroperitoneal localisation requires compartmental resection and is associated with a worse prognosis. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 5, 2021 Category: Cancer & Oncology Authors: Lars H. Lindner, Jean-Yves Blay, Alexander M.M. Eggermont, Rolf D. Issels Tags: Current Perspective Source Type: research

Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival
Ductal adenocarcinoma is an uncommon prostate cancer variant. Previous studies suggest that ductal variant histology may be associated with worse clinical outcomes, but these are difficult to interpret. To address this, we performed an international, multi-institutional study to describe the characteristics of ductal adenocarcinoma, particularly focussing on the effect of presence of ductal variant cancer on metastasis-free survival. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 5, 2021 Category: Cancer & Oncology Authors: Ken Chow, Justin Bed ő, Andrew Ryan, Dinesh Agarwal, Damien Bolton, Yee Chan, Philip Dundee, Mark Frydenberg, Marc A. Furrer, Jeremy Goad, Dennis Gyomber, Uri Hanegbi, Laurence Harewood, Dennis King, Alastair D. Lamb, Nathan Lawrentschuk, Peter Liodakis, Tags: Original Research Source Type: research

Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies
Triple-negative (TN) breast cancer (BC) is one of the most aggressive molecular subtype of this malignancy. Adjuvant chemotherapy (CT) in resected cases reduces the risk of death and relapse, with an absolute benefit that is dependent upon pathological features of resected specimens  [1]. Pathological tumour stage and nodal involvement are the main parameters of treatment choice after surgery. Despite neoadjuvant CT facilitates breast conservation in women with large tumours (≥cT2), the high chemosensitivity of TN subtype makes neoadjuvant CT more appealing even in lower sta ges ( (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 2, 2021 Category: Cancer & Oncology Authors: Fausto Petrelli, Maria Chiara Parati, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Andrea Luciani Tags: Letter to the Editor Source Type: research

Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2021 Category: Cancer & Oncology Authors: Takeshi Fukumoto, Nobuyuki Horita Tags: Letter to the Editor Source Type: research

DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients
In contrast to patients who present with advanced stage lung cancer and associated poor prognosis, patients with early-stage lung cancer may be candidates for curative treatments. The results of the NELSON lung cancer screening trial are expected to stimulate the development and implementation of a lung cancer screening strategy in most countries. Widespread use of chest computed tomography scans will also result in the detection of solitary pulmonary nodules. Because reliable biomarkers to distinguish between malignant and benign lesions are lacking, tissue-based histopathological diagnostics remain the gold standard. (So...
Source: European Journal of Cancer - March 1, 2021 Category: Cancer & Oncology Authors: Lea M. Schotten, Kaid Darwiche, Michal Seweryn, Vedat Yildiz, Peter J. Kneuertz, Wilfried E.E. Eberhardt, Stephan Eisenmann, Stefan Welter, Brianna E. Sisson, Maciej Pietrzak, Marcel Wiesweg, Till Ploenes, Thomas Hager, Kai He, Lutz Freitag, Clemens Aigne Tags: Original Research Source Type: research

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
XELAVIRI compared sequential (Arm A) versus initial (Arm B) irinotecan in combination with fluoropyrimidine plus bevacizumab in patients with metastatic colorectal cancer, trial identification: NCT01249638. In the full analysis set of the study, non-inferiority of time to failure of strategy (TFS) was not shown. The present analysis was performed to evaluate the effect of gender on treatment outcome and tolerability. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 27, 2021 Category: Cancer & Oncology Authors: Kathrin Heinrich, Dominik P. Modest, Ingrid Ricard, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Ullrich Graeven, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Clemens Giessen-Jung, Arndt Stahler, Tags: Original Research Source Type: research

Immunoglobin G / total antibody testing for SARS-CoV-2: a prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing 3 commercial tests
Coronavirus disease (COVID-19) is interfering heavily with the screening, diagnosis and treatment of cancer patients. Better knowledge of the seroprevalence and immune response after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in this population is important to manage them safely during the pandemic. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 27, 2021 Category: Cancer & Oncology Authors: Peter van Dam, Manon Huizing, Ella Roelant, An Hotterbeekx, Fien HR. De Winter, Samir Kumar-Singh, Pieter Moons, Zainab Amajoud, Christof Vulsteke, Lieselot Croes, Annelies Janssens, Zwi Berneman, Hans Prenen, Leander Meuris, Wim Vanden Berghe, Evelien Sm Tags: Original Research Source Type: research

Seroprevalence of SARs-CoV-2 among the staff and patients of a French cancer centre after first lockdown: the canSEROcov study
We report very low seroprevalence of antibodies against SARS-CoV-2 in the staff (caregiving and non-caregiving) and patients of a large cancer care centre in which strict hygiene, personal protection and social distancing measures were implemented. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 27, 2021 Category: Cancer & Oncology Authors: Sylvain Ladoire, Vincent Goussot, Emilie Redersdorff, Adele Cueff, Elise Ballot, Caroline Truntzer, Siavoshe Ayati, Leila Bengrine-Lefevre, Nathalie Bremaud, Bruno Coudert, Isabelle Desmoulins, Laure Favier, Cl éa Fraisse, Jean-David Fumet, Roxana Hanu, Tags: Original Research Source Type: research

Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer
The aim of the study was to develop and validate a deep learning radiomic nomogram (DLRN) for preoperatively assessing breast cancer pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) based on the pre- and post-treatment ultrasound. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 24, 2021 Category: Cancer & Oncology Authors: Meng Jiang, Chang-Li Li, Xiao-Mao Luo, Zhi-Rui Chuan, Wen-Zhi Lv, Xu Li, Xin-Wu Cui, Christoph F. Dietrich Tags: Original Research Source Type: research

Carvedilol blocks neural regulation of breast cancer progression in  vivo and is associated with reduced breast cancer mortality in patients
The sympathetic nervous system drives breast cancer progression through β-adrenergic receptor signalling. This discovery has led to the consideration of cardiac β-blocker drugs as novel strategies for anticancer therapies. Carvedilol is a β-blocker used in the management of cardiovascular disorders, anxiety, migraine and chemotherapy-induced cardiotoxicity. However, little is known about how carvedilol affects cancer-related outcomes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 24, 2021 Category: Cancer & Oncology Authors: Ryan D. Gillis, Edoardo Botteri, Aeson Chang, Alexandra I. Ziegler, Ni-Chun Chung, Cindy K. Pon, David M. Shackleford, Bettina K. Andreassen, Michelle L. Halls, Jillian G. Baker, Erica K. Sloan Tags: Original Research Source Type: research

RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers
With great interest we read the results of the pivotal French PIPOX trial [1]. The authors are to be congratulated for finishing the first phase I (3  + 3) dose-escalation trial assessing the maximum tolerated dose (MTD) of repetitive oxaliplatin-based pressurised intraperitoneal aerosol chemotherapy (PIPAC-oxaliplatin) in patients with unresectable peritoneal metastases of gastrointestinal cancers. After at least three months of systemic thera py before enrolment, patients in the PIPOX trial received four-to-six weekly intravenous leucovorin (20 mg/m2) and 5-fluorouracil (400 mg/m2) followed by PIPAC-o...
Source: European Journal of Cancer - February 24, 2021 Category: Cancer & Oncology Authors: Koen P. Rovers, Robin J. Lurvink, Maarten J. Deenen, Ignace H.J.T. de Hingh Tags: Letter to the Editor Source Type: research

Management of Cancer Patients during the COVID-19 Pandemic: the Italian perspective on the Second Wave
The novel Coronavirus Disease 2019 (COVID-19) pandemic has been an overwhelming challenge for worldwide health systems. Since the beginning of year 2020, COVID-19 has represented a potential harm for cancer patients and has often hindered oncology care. The Collegio Italiano dei Primari Oncologi Medici (CIPOMO) is an Italian association of head physicians in oncology departments, which promotes working and research activities in oncology on a national basis. During the second wave of COVID-19 pandemic, the CIPOMO promoted a national survey aiming to evaluate the impact of COVID-19 on oncologists ’ clinical activity a...
Source: European Journal of Cancer - February 24, 2021 Category: Cancer & Oncology Authors: Alice Indini, Graziella Pinotti, Fabrizio Artioli, Carlo Aschele, Daniele Bernardi, Alfredo Butera, Efisio Defraia, Gianpiero Fasola, Teresa Gamucci, Monica Giordano, Antonino Iaria, Silvana Leo, Angela Stefania Ribecco, Riccardo Rossetti, Clementina Sava Tags: Original Research Source Type: research

Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action
Coronavirus disease 2019 (COVID-19) has affected more than 96 million people worldwide, leading the World Health Organization (WHO) to declare a pandemic in March 2020. Although an optimal medical treatment of COVID-19 remains uncertain, an unprecedented global effort to develop an effective vaccine hopes to restore pre-pandemic conditions. Since cancer patients as a group  have been shown to be at higher risk of severe COVID-19, the development of safe and effective vaccines is crucial. However, cancer patients may be underrepresented in ongoing phase 3 randomized clinical trials investigating COVID-19 vaccines. (So...
Source: European Journal of Cancer - February 24, 2021 Category: Cancer & Oncology Authors: Chiara Corti, Edoardo Crimini, Paolo Tarantino, Gabriella Pravettoni, Alexander M.M. Eggermont, Suzette Delaloge, Giuseppe Curigliano Tags: Review Source Type: research

New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of national lockdown
This study aimed at assessing the number of new cancers during and after the lockdown. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 24, 2021 Category: Cancer & Oncology Authors: Emmanuelle Kempf, Guillaume Lam é, Richard Layese, Sonia Priou, Gilles Chatellier, Hedi Chaieb, Marc-Antoine Benderra, Ali Bellamine, Romain Bey, Stéphane Bréant, Gilles Galula, Namik Taright, Xavier Tannier, Thomas Guyet, Elisa Salamanca, Etienne Audu Tags: Original Research Source Type: research

Telomerase reverse transcriptase promoter mutation – and O6-methylguanine DNA methyltransferase promoter methylation–mediated sensitivity to temozolomide in isocitrate dehydrogenase–wild-type glioblastoma: is there a link?
Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH) –wild-type glioblastoma is essentially limited to patients with O6-methylguanine DNA methyltransferase (MGMT) promoter–methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TERT) promoter hotspot mutations may have an impact on the prognostic role of the MGMT status in patients with glioblastoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 23, 2021 Category: Cancer & Oncology Authors: Dorothee Gramatzki, J örg Felsberg, Bettina Hentschel, Marietta Wolter, Gabriele Schackert, Manfred Westphal, Luca Regli, Niklas Thon, Marcos Tatagiba, Wolfgang Wick, Uwe Schlegel, Dietmar Krex, Jakob Matschke, Patrick Roth, Marian P. Suresh, Marcel A. K Tags: Original Research Source Type: research

Prolonged SARS-CoV-2 viral shedding in patients with solid tumors and associated factors
SARS-CoV-2 is a highly contagious virus and can cause potentially fatal complications in cancer patients1-4. Until now, the most accurate and common methods to detect active viral infection are: (1) a positive RT-PCR, (2) a serological test (IgM+ and IgG-), (3) or a positive antigen test5. Previous studies have characterized time length of viral shedding in immunocompetent patients6; however, there are scarce reports on immunosuppressed cancer patients. Aydillo et al. studied shedding of viable SARS-CoV-2 in transplanted hematological patients or those receiving CAR-T cell therapy7. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 23, 2021 Category: Cancer & Oncology Authors: Jacobo Rogado, Pedro Gull ón, Berta Obispo, Gloria Serrano, Miguel Ángel Lara Tags: Letter to the Editor Source Type: research

Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer
Intraductal (IDC) and cribriform (CRIB) histologies in prostate cancer have been associated with germline BRCA2 (gBRCA2) mutations in small retrospective series, leading to the recommendation of genetic testing for patients with IDC in the primary tumour. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 21, 2021 Category: Cancer & Oncology Authors: Rebeca Lozano, Daniela C. Salles, Shahneen Sandhu, Isabel M. Arag ón, Heather Thorne, Fernando López-Campos, José Rubio-Briones, Ana M. Gutierrez-Pecharroman, Laneisha Maldonado, Tomas di Domenico, Alejandro Sanz, Juan D. Prieto, Isabel García, María Tags: Original Research Source Type: research

The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism
The mechanisms underlying the contribution of primary tumour to pre-metastatic niche formation remains largely unknown in hepatocellular carcinoma (HCC). We previously reported that the released LOXL2 from HCC cells under higher stiffness stimulation facilitated the formation of lung pre-metastatic niche. Here, we further clarified the pathological role of LOXL2 in promoting lung pre-metastatic niche formation and lung metastasis occurrence in HCC and its relevant molecular mechanism. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 20, 2021 Category: Cancer & Oncology Authors: Sifan Wu, Xiaoxia Xing, Yaohui Wang, Xi Zhang, Miao Li, Mimi Wang, Zhiming Wang, Jie Chen, Dongmei Gao, Yan Zhao, Rongxin Chen, Zhenggang Ren, Kezhi Zhang, Jiefeng Cui Tags: Original Research Source Type: research

Neoadjuvant and adjuvant end-points in health technology assessment in oncology
Health technology assessment (HTA) of clinical and economic value of a new intervention is an integral step in providing the access of patients to innovative cancer care and treatment. Overall survival (OS) is the preferred criterion for demonstrating the therapeutic efficacy in HTA given its direct clinical and patient relevance. However, with often long life expectancy of patients with early cancer, analysis of OS becomes less practical. Partially due to this reason, pathological complete response (pCR) and time-to-event end-points like disease-free survival are frequently incorporated into the pivotal clinical trials in...
Source: European Journal of Cancer - February 19, 2021 Category: Cancer & Oncology Authors: Nadia Harbeck, Andreas Schneeweiss, Peter Thuss-Patience, Kurt Miller, Claus Garbe, Frank Griesinger, Wilfried E.E. Eberhardt, Jens P. Klussmann, Barbara Wollenberg, Marc-Oliver Grimm, Thomas Zander, Diana L üftner Tags: Review Source Type: research

Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
Lung metastases may worsen overall survival (OS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). We investigated (post hoc) the impact of lung metastases on survival in SELECT (a phase 3 study). (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 19, 2021 Category: Cancer & Oncology Authors: Makoto Tahara, Naomi Kiyota, Ana O. Hoff, Corin Badiu, Taofeek K. Owonikoko, Corina E. Dutcus, Takuya Suzuki, Min Ren, Lori J. Wirth Tags: Original Research Source Type: research

Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E –mutated colorectal cancer
Approximately, 10% of metastatic colorectal cancers display BRAF V600E mutation. Although originally associated with poor outcomes, new targeted therapies have improved their prognosis. The phase III multicenter randomised BEACON trial  showed that, second-line triple therapy combining binimetinib, encorafenib and cetuximab improved response rate, as well as progression-free and overall survival among these patients [1]. No nephrotoxicity has yet been reported with the association of these three drugs. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 19, 2021 Category: Cancer & Oncology Authors: Romain Stammler, Claire Gallois, Julien Taieb, Jean-Paul Duong, Alexandre Karras, Eric Thervet, H élène Lazareth Tags: Letter to the Editor Source Type: research

Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma
The interesting work by Ben-Betzalel et  al. [1] highlighted the potential incidence of immune-related adverse events (irAEs), which are typically associated with immune-checkpoint inhibitors, among patients with melanoma treated with BRAF and MEK inhibitors. In fact, these tyrosine-kinase inhibitors (TKIs) exert several immunomodulating effects, mainly linked to increased tumour-released antigens, increased expression of major histocompatibility complex class I, increased recruitment of CD8+ T cells, inhibition of T regulatory cells and decreased programmed death ligand 1 (PD-L1) expression [2,3]. (Source: Europ...
Source: European Journal of Cancer - February 19, 2021 Category: Cancer & Oncology Authors: Alessandro Di Federico, Daria Maria Filippini, Francesca Sperandi, Andrea Ardizzoni, Barbara Melotti Tags: Letter to the Editor Source Type: research

Editorial for Cribriform architecture prostatic adenocarcinoma in needle biopsy is a strong independent predictor for lymph node metastases in radical prostatectomy (M. Downes  et al.) and Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival (K. Chow et al.)
In this volume of the European Journal of Cancer, two complementary studies regarding the histopathology of Gleason grade IV (GG4) prostate cancer (PCa) are presented. Herein, the authors explore specific histopathological aspects of GG4 PCa predictive of poor outcome and lymph node status. The common message underlined by both reports is that features accessible via routine histology of prostate biopsy or prostatectomy specimens yield valuable information regarding both patient outcome and specific molecular changes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 19, 2021 Category: Cancer & Oncology Authors: Eva Comp érat Tags: Editorial Source Type: research

Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488]
The authors regret that the dosage details for trastuzumab in the original publication were incorrectly given as 8 and 6 mg/m2. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 18, 2021 Category: Cancer & Oncology Authors: Min-Hee Ryu, Changhoon Yoo, Jong Gwang Kim, Baek-Yeol Ryoo, Young Soo Park, Sook Ryun Park, Hye-Suk Han, Ik Joo Chung, Eun-Kee Song, Kyung Hee Lee, Seok Yun Kang, Yoon-Koo Kang Tags: Corrigendum Source Type: research

SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: recommendations from the French society for Immuno-Therapy of Cancer (FITC)
Since December 2019, the emergence of the severe acute respiratory syndrome (SARS)- coronavirus (CoV)-2, responsible for COVID-19 and its worldwide spread led to devastating medical, economic and social consequences. Recently approved anti-SARS-CoV-2 vaccines (SC2V) offer a new hope to end this crisis. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 18, 2021 Category: Cancer & Oncology Authors: Marie-L éa Gauci, Clélia Coutzac, Roch Houot, Aurélien Marabelle, Céleste Lebbé Tags: Letter to the Editor Source Type: research

Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis
To compare overall survival (OS) in patients who underwent surgery for early-stage pancreatic adenocarcinoma (rPca) based on sequence (NAT, neoadjuvant therapy and/or AT, adjuvant therapy) and type (SA, single-agent or MA, multi-agent) of chemotherapy received. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Aileen Deng, Chun Wang, Steven J. Cohen, Jordan M. Winter, James Posey, Charles Yeo, Atrayee Basu Mallick Tags: Original Research Source Type: research

Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox  study
Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event (IRAE). The aim was to describe the epidemiology, risks factors, clinical, and laboratory characteristics of these renal adverse events (AEs) in a real-life cohort treatment. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: M. Espi, C. Teuma, E. Novel-Catin, D. Maillet, P.J. Souquet, S. Dalle, L. Koppe, D. Fouque Tags: Original Research Source Type: research

Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma
This study reports results from the prespecified health-related quality of life (HRQoL) and neurological deterioration-free survival (NDFS) exploratory analysis. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Paul M.J. Clement, Linda Dirven, Marica Eoli, Juan M. Sepulveda-Sanchez, Annemiek M.E. Walenkamp, Jean S. Frenel, Enrico Franceschi, Michael Weller, Olivier Chinot, Filip Y.F.L. De Vos, Nicolas Whenham, Paul Sanghera, Jim Looman, Madan G. Kundu, Jan Peter Tags: Original Research Source Type: research

Patterns and prognostic significance of cutaneous immune-related adverse events in non –small cell lung cancer
Certain cutaneous immune-related adverse events (cirAEs) arising with programmed death-1/ligand-1 (PD-1, PD-L1) blockade may be associated with survival benefit [1,5]. However, whether this benefit persists across all cirAE and cancer subtypes remains unclear, as melanoma patients have been overrepresented in prior work and analyses of confirmed cirAEs by category using robust statistical methodologies have been scant [1 –5]. Since the therapeutic effects of PD-1/PD-L1 therapy hinge upon immune responses in the tumour microenvironment, cancer type could affect the relationship between cirAEs and clinical outcomes, bu...
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Leah L. Thompson, Emily R. Nadelmann, Amy E. Blum, Jaewon Yoon, Nicole J. Polyakov, Ruth D. Kagan, Justin F. Gainor, Meghan J. Mooradian, Steven T. Chen Tags: Letter to the Editor Source Type: research

Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx
This phase I study assessed the safety of first-in-class radioenhancer nanoparticles, NBTXR3, in elderly or frail patients with locally advanced head and neck squamous cell carcinoma (HNSCC), ineligible for chemoradiation. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Caroline Hoffmann, Valentin Calugaru, Edith Borcoman, Victor Moreno, Emiliano Calvo, Xavier Liem, S ébastien Salas, Bernard Doger, Thomas Jouffroy, Xavier Mirabel, Jose Rodriguez, Anne Chilles, Katell Bernois, Mikaela Dimitriu, Nicolas Fakhry, Stéphanie Tags: Original Research Source Type: research

Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. While the extracellular matrix component  plays an integral role in PDAC pathogenesis and mediating chemoresistance, its role in predicting response to chemotherapy in patients with PDAC remains unclear. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Yasuyuki Okada, Satoshi Nishiwada, Kensuke Yamamura, Masayuki Sho, Hideo Baba, Tetsuji Takayama, Ajay Goel Tags: Original Research Source Type: research

Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis
Neuroendocrine differentiation has been extensively associated with worse prognosis and to mechanisms of therapy resistance in several epithelial cancers. A high prevalence of neuroendocrine differentiation was recently described in V600EBRAF-mutated (BRAFmt) metastatic colorectal cancers (mCRCs) but no data are available about its prognostic impact in this setting. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Matteo Fassan, Massimo Milione, Giulia Maddalena, Chiara Cremolini, Marta Schirripa, Filippo Pietrantonio, Nicoletta Pella, Emanuela Dell ’Aquila, Elisa Sperti, Clizia Zichi, Francesca Bergamo, Marco Volante, Alessandra Boccaccino, Federica Morano, Fran Tags: Original Research Source Type: research

Bromodomain and extra-terminal  inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE
Based on biology and pre-clinical data, bromodomain and extra-terminal (BET) inhibitors have at least three potential roles in paediatric malignancies: NUT (nuclear protein in testis) carcinomas, MYC/MYCN-driven cancers  and fusion-driven malignancies. However, there are now at least 10 BET inhibitors in development, with a limited relevant paediatric population in which to evaluate these medicinal products. Therefore, a meeting was convened with the specific aim to develop a consensus among relevant biopharmaceut ical companies, academic researchers, as well as patient and family advocates, about the development of B...
Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Andrew DJ. Pearson, Steven G. DuBois, Vickie Buenger, Mark Kieran, Kimberly Stegmaier, Pratiti Bandopadhayay, Kelly Bennett, Franck Bourdeaut, Patrick A. Brown, Louis Chesler, Jessica Clymer, Elizabeth Fox, Christopher A. French, Eva Germovsek, Francis J. Tags: Review Source Type: research

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours
ABTL0812 is an autophagy inducer that promotes cancer cell death by activation of cytotoxic autophagy selectively in tumour cells. ABTL0812 induces endoplasmic reticulum stress and blocks the Akt-mTOR axis; both actions converge to activate a robust and sustained autophagy leading to cancer cell death. Preclinical data supported the initiation of clinical trials in patients with cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: Laura Vidal, Ivan Victoria, Lydia Gaba, Marta Gil Mart ín, Mercè Brunet, Helena Colom, Marc Cortal, Mariana Gómez-Ferrería, Marc Yeste-Velasco, Antonio Perez, Jordi Rodon, Davendra P.S. Sohal, José Miguel Lizcano, Carles Domènech, José Alfón, Pere Tags: Original Research Source Type: research

Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome –positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study
To evaluate long-term durability of blinatumomab, a BiTE ® (bispecific T-cell engager) molecule, in adults with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver Ottmann, Nicola G ökbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine A. Tuglus, Joan D. Morris, Anthony Stein Tags: Original Research Source Type: research

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie  with an integrated analysis of the ‘burden of therapy’ method
Targeting the epidermal growth factor receptor  pathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker approved in non–small-cell lung cancer. This open-label, multicenter, randomised phase II trial evaluated gemcitabine plus afatinib (Gem/afatinib) versus gemcitabine (Gem) alone as first-line treatment for metastatic pancreatic cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: M. Haas, D.T. Waldschmidt, M. Stahl, A. Reinacher-Schick, J. Freiberg-Richter, L. Fischer von Weikersthal, F. Kaiser, S. Kanzler, N. Frickhofen, T. Seufferlein, T. Dechow, R. Mahlberg, P. Malfertheiner, G. Illerhaus, S. Kubicka, A. Abdul-Ahad, R. Snijder, Tags: Original Research Source Type: research

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: Valentina Ambrosini, Jolanta Kunikowska, Eric Baudin, Lisa Bodei, Catherine Bouvier, Jaume Capdevila, Marta Cremonesi, Wouter W. de Herder, Clarisse Dromain, Massimo Falconi, Melpomeni Fani, Stefano Fanti, Rodney J. Hicks, Levent Kabasakal, Gregory Kaltsa Tags: Review Source Type: research

Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab
Porocarcinoma (PC), or malignant eccrine poroma, is a rare skin neoplasm of the intraepidermal ductal portion of the sweat gland, accounting for 0.005 –0.01% of all malignant epithelial tumours [1,2]. The main risk factors are irradiation, lymphoedema and trauma, but it may also be associated with Hodgkin's and Paget's disease, chronic lymphocytic leukaemia, pernicious anaemia, HIV infection, sarcoidosis and xeroderma pigmentosum [2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: Francesca Comito, Maria C. Nigro, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni Tags: Letter to the Editor Source Type: research

RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
Rat sarcoma (RAS) oncogenes have intensively been investigated during the last decades. Taking into account all human tumours, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene is the most frequently mutated (about 22%) among the three isoforms, followed by Neuroblastoma RAS Viral Oncogene Homolog (NRAS) (8%) and Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) (3%). In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non –small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients because of their prognostic and predictive roles. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: Umberto Malapelle, Francesco Passiglia, Chiara Cremolini, Maria Lucia Reale, Francesco Pepe, Pasquale Pisapia, Antonio Avallone, Diego Cortinovis, Alfonso De Stefano, Matteo Fassan, Gabriella Fontanini, Domenico Galetta, Calogero Lauricella, Angela List Tags: Review Source Type: research